Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ablynx NV completes two further phase I clinical studies
Ablynx NV:Says that it has obtained positive results from two additional Phase I studies, utilising its wholly owned anti-RSV Nanobody(ALX-0171) designed for the treatment of Respiratory Syncytial Viral (RSV) infections.Following on from the successful Phase I study reported in Sept. 2012.ALX-0171 is Ablynx's first inhaled Nanobody and was administered to adults via a nebulizer in a safety study and in a pharmacokinetic study.
Latest Key Developments in Biotechnology
- Genetic Technologies Ltd announces divestment of Australian heritage business to Primary Health Care Ltd's subsidiary
- Starpharma Holdings Ltd completes A$18 mln placement; SPP to follow
- Dermira Inc sees IPO price between $14.00 and $16.00 per share - Form S-1/A
- Microlin Bio Inc announces withdrawal of registration statement on Form S-1 - Form RW
- Share this
- Digg this